Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Pearls on the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in CKD in T2D

Drs Diana Isaacs and Joshua J. Neumiller summarize key information on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and the role of the pharmacist in caring for these patients.
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Released: May 17, 2022

In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:

  • Overview of chronic kidney disease
  • Guideline recommendations
  • Evidence for finerenone
  • Role of the pharmacist

Information on this Educational Activity

Faculty

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, has disclosed that she has received consulting fees from Abbott, Dexcom, Insulet, Klinio, Medtronic, and Novo Nordisk.
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has disclosed that he has received consulting fees from Bayer, Dexcom, Novo Nordisk, and Sanofi.

Program Medium

This program has been made available online.

Acknowledgements

Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Dr Geoffrey C. Wall discusses how updated guidelines inform the selection of appropriate therapy for patients with severe asthma, from ProCE

Geoffrey C. Wall, PharmD, FCCP, BCPS Released: June 7, 2022

Dr Jamie McConaha discusses the current understanding of atopic dermatitis pathophysiology and the latest biologic therapies used for treatment, from ProCE

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES Released: June 1, 2022

Expert commentary and downloadable slides featuring guidance for pharmacists on personalizing care for patients with moderate to severe AD

Sarah Lant, PharmD Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES Released: May 18, 2022

Slideset with expert insights on the optimal management of severe asthma to improve clinical and economic outcomes from ProCE.

Suzanne G. Bollmeier, PharmD, FCCP, BCPS, AE-C Geoffrey C. Wall, PharmD, FCCP, BCPS Released: May 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings